

an Fc portion of an IgA antibody, wherein said Fc portion comprises a CH2 domain and a CH3 domain but does not comprise a hinge region; and  
a FRA ligand,  
thereby recruiting and activating neutrophils to destroy the FRA-expressing cancer cell in the subject.

**16.** The method of claim **15**, wherein the FRA ligand comprises folate or a folate analog.

**17.** The method of claim **15**, wherein the cancer is breast cancer, ovarian cancer, or lung cancer.

**18.** The method of claim **15**, wherein the cancer is triple negative breast cancer.

**19.** The method of claim **15**, wherein the cancer includes cancer cells that lack receptors for one or more of estrogen, progesterone and epithelial growth factor.

**20.** The method of claim **15**, wherein the conjugate is administered to the subject intravenously.

\* \* \* \* \*